Trials / Completed
CompletedNCT00198536
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ecabet 2.83% | |
| DRUG | Ecabet 3.70% | |
| DRUG | Vehicle |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2005-12-01
- Completion
- 2005-12-01
- First posted
- 2005-09-20
- Last updated
- 2013-03-14
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00198536. Inclusion in this directory is not an endorsement.